Black Diamond Therapeutics
BDTX
96 hedge funds and large institutions have $64.9M invested in Black Diamond Therapeutics in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 32 closing their positions.
378% more call options, than puts
Call options by funds: $779K | Put options by funds: $163K
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
6.06% less ownership
Funds ownership: 67.23% → 61.17% (-6.1%)
8% less funds holding
Funds holding: 104 → 96 (-8)
21% less capital invested
Capital invested by funds: $82M → $64.9M (-$17.1M)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.87M |
| 2 |
DCM
Defilade Capital Management
Emeryville,
California
|
+$4.1M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.67M |
| 4 |
AIC
AWM Investment Company
New York
|
+$1.16M |
| 5 |
Renaissance Technologies
New York
|
+$779K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$16M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$1.8M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.39M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.23M |
| 5 |
Man Group
London,
United Kingdom
|
-$1.19M |
BDTX Hedge Fund Activity: Q2 2026 in Review
96 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2026, worth a combined $64.9M — down 21% from $82M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of BDTX and 25 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 35 added.
The largest buyer was BlackRock, adding an estimated $6.87M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $16M.
- 96 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2026, down from 104 in Q1 2026.
- Funds reported $64.9M of Black Diamond Therapeutics stock for Q2 2026, down 21% quarter-over-quarter.
- 25 funds opened new Black Diamond Therapeutics positions in Q2 2026 and 32 closed out, a net change of -7 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2026 was BlackRock, an estimated $6.87M added.
- The largest Black Diamond Therapeutics seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2026.